6473 related articles for article (PubMed ID: 23348793)
1. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.
Stelter L; Evans MJ; Jungbluth AA; Longo VA; Zanzonico P; Ritter G; Bomalaski JS; Old L; Larson SM
Mol Imaging; 2013; 12(1):67-73. PubMed ID: 23348793
[TBL] [Abstract][Full Text] [Related]
2. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
3. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
[TBL] [Abstract][Full Text] [Related]
4. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
[TBL] [Abstract][Full Text] [Related]
5. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
[TBL] [Abstract][Full Text] [Related]
6. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C
Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Bowles TL; Kim R; Galante J; Parsons CM; Virudachalam S; Kung HJ; Bold RJ
Int J Cancer; 2008 Oct; 123(8):1950-5. PubMed ID: 18661517
[TBL] [Abstract][Full Text] [Related]
8. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Yoon CY; Shim YJ; Kim EH; Lee JH; Won NH; Kim JH; Park IS; Yoon DK; Min BH
Int J Cancer; 2007 Feb; 120(4):897-905. PubMed ID: 17096330
[TBL] [Abstract][Full Text] [Related]
9. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Feun LG; Marini A; Walker G; Elgart G; Moffat F; Rodgers SE; Wu CJ; You M; Wangpaichitr M; Kuo MT; Sisson W; Jungbluth AA; Bomalaski J; Savaraj N
Br J Cancer; 2012 Apr; 106(9):1481-5. PubMed ID: 22472884
[TBL] [Abstract][Full Text] [Related]
10. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
Kim RH; Coates JM; Bowles TL; McNerney GP; Sutcliffe J; Jung JU; Gandour-Edwards R; Chuang FY; Bold RJ; Kung HJ
Cancer Res; 2009 Jan; 69(2):700-8. PubMed ID: 19147587
[TBL] [Abstract][Full Text] [Related]
11. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Kuo MT; Savaraj N; Feun LG
Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
[TBL] [Abstract][Full Text] [Related]
12. L-arginine enhances arginine deiminase induced human lymphoma cell growth inhibition through NF-kBp65 and p53 expression in vitro.
Shu XL; Liu XL; Zhong JX; Liu J
Eur Rev Med Pharmacol Sci; 2014; 18(15):2124-31. PubMed ID: 25070816
[TBL] [Abstract][Full Text] [Related]
13. Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.
Stelter L; Evans MJ; Jungbluth AA; Zanzonico P; Ritter G; Ku T; Rosenfeld E; Bomalaski JS; Old L; Larson SM
J Nucl Med; 2012 Feb; 53(2):281-6. PubMed ID: 22228793
[TBL] [Abstract][Full Text] [Related]
14. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
Ascierto PA; Scala S; Castello G; Daponte A; Simeone E; Ottaiano A; Beneduce G; De Rosa V; Izzo F; Melucci MT; Ensor CM; Prestayko AW; Holtsberg FW; Bomalaski JS; Clark MA; Savaraj N; Feun LG; Logan TF
J Clin Oncol; 2005 Oct; 23(30):7660-8. PubMed ID: 16234528
[TBL] [Abstract][Full Text] [Related]
15. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4.
Tsai WB; Aiba I; Lee SY; Feun L; Savaraj N; Kuo MT
Mol Cancer Ther; 2009 Dec; 8(12):3223-33. PubMed ID: 19934275
[TBL] [Abstract][Full Text] [Related]
16. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
17. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
Kelly MP; Jungbluth AA; Wu BW; Bomalaski J; Old LJ; Ritter G
Br J Cancer; 2012 Jan; 106(2):324-32. PubMed ID: 22134507
[TBL] [Abstract][Full Text] [Related]
18. Amino Acid Uptake Measured by [
Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
[No Abstract] [Full Text] [Related]
19. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
Tsai WB; Aiba I; Long Y; Lin HK; Feun L; Savaraj N; Kuo MT
Cancer Res; 2012 May; 72(10):2622-33. PubMed ID: 22461507
[TBL] [Abstract][Full Text] [Related]
20. Arginine deprivation as a targeted therapy for cancer.
Feun L; You M; Wu CJ; Kuo MT; Wangpaichitr M; Spector S; Savaraj N
Curr Pharm Des; 2008; 14(11):1049-57. PubMed ID: 18473854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
